par Raymond, Éric E.;Faivre, Sandrine;Alexandre, Jérôme;Goldwasser, François;Besse-Hammer, Tatiana;Awada, Ahmad
;Gianella-Borradori, Athos;Jego, V.;Trandafir, Lucia;Rejeb, Narmyn
Référence Investigational new drugs, 32, 1, page (94-103)
Publication Publié, 2014
;Gianella-Borradori, Athos;Jego, V.;Trandafir, Lucia;Rejeb, NarmynRéférence Investigational new drugs, 32, 1, page (94-103)
Publication Publié, 2014
Article révisé par les pairs
| Titre: |
|
| Auteur: | Raymond, Éric E.; Faivre, Sandrine; Alexandre, Jérôme; Goldwasser, François; Besse-Hammer, Tatiana; Awada, Ahmad; Gianella-Borradori, Athos; Jego, V.; Trandafir, Lucia; Rejeb, Narmyn |
| Informations sur la publication: | Investigational new drugs, 32, 1, page (94-103) |
| Statut de publication: | Publié, 2014 |
| Sujet CREF: | Cancérologie |
| Pharmacologie | |
| Mots-clés: | Aurora kinase inhibitor |
| Mitosis | |
| MSC1992371A | |
| Neutropenia | |
| Phase l | |
| Targeted therapy | |
| MeSH keywords: | Adult |
| Aged | |
| Aged, 80 and over | |
| Antineoplastic Agents -- adverse effects -- blood -- pharmacokinetics -- therapeutic use | |
| Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- blood -- pharmacokinetics -- therapeutic use | |
| Demography | |
| Deoxycytidine -- analogs & derivatives | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Male | |
| Maximum Tolerated Dose | |
| Middle Aged | |
| Neoplasms -- blood -- drug therapy | |
| Norbornanes -- adverse effects -- blood -- pharmacokinetics -- therapeutic use | |
| Protein Kinase Inhibitors -- adverse effects -- blood -- pharmacokinetics -- therapeutic use | |
| Pyrimidines -- adverse effects -- blood -- pharmacokinetics -- therapeutic use | |
| Young Adult | |
| Note générale: | SCOPUS: ar.j |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0167-6997 |
| info:doi/10.1007/s10637-013-9950-y | |
| info:scp/84899076412 | |
| info:pmid/23539344 |



